Table 5.
Outcome of first-line ART in 17 participants
| PID | % DRM for HXB2 position: |
ART | VF | Duration of ART (days) | UDS to ART (days) | DRM at VF | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 | 103 | 181 | 184 | 188 | 215 | ||||||
| A7 | 0.1 | 0.94 | 0 | 0.39 | 0 | 0 | 3TC/AZT/IND | Yes** | 148 | 1 | M184MV |
| C4 | 0 | 0 | 0 | 0 | 0 | 0.51 | 3TC/AZT/NFV | Yes | 579 | 1 | M184V, D30N, N88D |
| I4 | *0.23 | 99.77 | *0.06 | 0.2 | 0.15 | *0.08 | 3TC/TDF/ATV/RTV | No | 1040 | 1223 | |
| I9 | 0.3 | 0.66 | 0 | 0.82 | 0 | 0 | 3TC/D4T/TDF/EFV | No | 1743 | 10 | |
| J5 | 0 | IR | 0 | 0 | 0 | 0 | 3TC/AZT/SQV/RTV | Yes** | 180 | 3 | A71V |
| J6 | 0.6 | 0 | 0 | 1.9 | *0.38 | 0 | 3TC/AZT/EFV | No | 1965 | 102 | |
| J8 | 1.36 | IR | 0 | 1 | 0.17 | 0 | 3TC/ABC/D4T/APV/RTV | Yes | 314 | 1 | NONE |
| L1 | 0 | IR | 0 | 0.56 | 0.56 | 0 | 3TC/AZT/LPV/RTV | Yes** | 277 | 20 | NONE |
| L6 | 0.27 | 2.99 | 0.12 | 0.12 | 0 | 0 | FTC/TDF/ATZ/RTV | No | 115 | 613 | |
| M4 | 0.09 | 0.5 | 0 | 0.13 | 99.35 | 0.17 | 3TC/AZT/ABC/LPV/RTV | No | 1500 | 19 | |
| N0 | 0.23 | IR | 0.13 | 0.26 | 0.13 | 0 | FTC/TDF/EFV | No | 840 | 574 | |
| R2 | *2.27 | 17.74 | 0 | *0.89 | *0.81 | 0 | FTC/TDF/EFV | No | 86 | 857 | |
| R3 | 0 | 0 | 0 | 0.17 | 0 | 0 | FTC/TDF/EFV | No | 28 | 983 | |
| R4 | 0 | IR | 0 | 0 | 0 | IR | ABC/3TC/EFV | No | 168 | 676 | |
| S3 | IR | 0 | 0 | 0 | 0 | IR | TDV/FTC/ATZ/RTV | Yes | 378 | 10 | L10I |
| U1 | *0.2 | IR | *0.17 | *0.17 | *0.19 | 0 | FTC/TDF/EFV | No | 34 | 490 | |
| U7 | *0.61 | 100 | *0.25 | *0.25 | 0 | 0 | ABC/3TC/FOS/RTV | No | 227 | 233 | |
PID, patient identification number; ART, antiretroviral therapy; VF, virologic failure of ART; IR, insufficient reads at site/sample;*, DRM that were found in only one of repeated runs; **,likely nonadherence to ART. Bold type indicates percentages of drug resistance mutations (% DRM) exceeding the background error rate. Underlining indicates those DRM that were detected by both population-based sequencing and SGS. Duration of ART, follow-up in days from therapy start to viral failure or to last available time point; UDS to ART, follow-up time in days from UDS to ART start; 3TC, lamivudine; AZT, zidovudine; IND, indinavir; NFV, nelfinavir; TDF, tenofovir; ATV, atazanavir; RTV, ritonavir; D4T, stavudine; EFV, efavirenz; SQV, sequinavir; ABC, abacavir; APV, amprenavir; LPV, lopinavir; FTC, emtricitabine; FOS, fosamprenavir.